Intravitreal Bevacizumab for Incontinentia Pigmenti

• Published in: Journal of pediatric ophthalmology and strabismus Vol. 50; no. 6; pp. e52 - e54
• Main Authors: Shah, Parag K., Bachu, Sandeep, Narendran, Venkatapathy, Kalpana, Narendran, David, Jeevamala, Srinivas, Chakravarthi R.
• Format: Journal Article
• Language: English
• Published: Thorofare, NJ SLACK Incorporated 29.10.2013; SLACK INCORPORATED
• Subjects: Abortion; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal, Humanized - administration & dosage; Bevacizumab; Biopsy; Cryotherapy; Dermatology; Eye diseases; Eyes & eyesight; Female; Fluorescein Angiography; Fundus Oculi; Genetic disorders; Hemorrhage; Humans; Incontinentia Pigmenti - complications; Incontinentia Pigmenti - diagnosis; Infant, Newborn; Intravitreal Injections; Lasers; Medical imaging; Monoclonal antibodies; Ophthalmology; Pediatrics; Pigments; Retina; Retinal detachment; Skin - pathology; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A; Vitreoretinopathy, Proliferative - diagnosis; Vitreoretinopathy, Proliferative - drug therapy; Tamil Nadu India; India
• ISSN: 0191-3913; 1938-2405; 1938-2405
• DOI: 10.3928/01913913-20131022-01

Two eyes of two siblings affected with incontinentia pigmenti having severe proliferative retinopathy are reported. Both cases showed complete resolution of new vessels after a single injection of intravitreal bevacizumab. At 7 months of follow-up, the first case revealed vascularization to the mid-periphery including a vascularized fovea (which was avascular before injection) but recurrence of some peripheral neovascularization, which was treated by conventional laser. The second case had no recurrence. No ocular or systemic adverse effects were observed. Intravitreal bevacizumab as an adjunct therapy in incontinentia pigmenti with macular ischemia could be beneficial. [J Pediatr Ophthalmol Strabismus 2013;50:e52–e54.]